Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis

The Lancet. Haematology
Shahrukh HashmiOlle Ringden

Abstract

Graft-versus-host disease (GVHD) is the major limitation of allogeneic haemopoietic stem-cell transplantation (HSCT), for which no approved treatments are available. Use of mesenchymal stromal cells (MSCs) has become standard practice in some European countries, but controversy exists for their benefit. The aim of this meta-analysis was to analyse available evidence for the benefit of MSC treatments in steroid-resistant acute GVHD. We did a systematic review and meta-analysis to assess response to and survival after MSC treatment in patients with steroid-refractory acute GVHD. We searched MEDLINE, Embase, Ovid, and Cochrane Central databases for published studies, and we used ClinicalTrials.gov and other websites to find unpublished studies and conference abstracts. We included prospective and retrospective studies in which MSCs were administered to patients with steroid-refractory acute GVHD. Data were extracted independently by two investigators based on strict selection criteria. A random-effects model was used to pool outcomes across studies because of anticipated heterogeneity. Our primary outcome was survival at 6 months from the first infusion of MSCs. We identified 628 citations with our search, of which 610 were exclud...Continue Reading

References

Apr 10, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sally AraiGeorgia B Vogelsang
Apr 23, 1960·Nature·B NAKICV SILOBRCIC
Apr 28, 2006·The New England Journal of Medicine·Edward A Copelan
Sep 18, 2007·Blood Cells, Molecules & Diseases·Ingo MüllerRupert Handgretinger
May 13, 2008·Lancet·Katarina Le BlancUNKNOWN Developmental Committee of the European Group for Blood and Marrow Transplantation
Jun 23, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Partow KebriaeiJoseph Uberti
May 12, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Vinod K PrasadJoanne Kurtzberg
Aug 26, 2010·Cytotherapy·Darwin J ProckopArmand Keating
Aug 9, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lena von BahrOlle Ringdén
Dec 21, 2011·International Journal of Hematology·Richard HerrmannPaul Cannell
Apr 19, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul J MartinPaul A Carpenter
Apr 27, 2012·British Journal of Haematology·Fiona L DignanUNKNOWN British Society for Blood and Marrow Transplantation
Oct 19, 2012·The New England Journal of Medicine·Claudio AnasettiUNKNOWN Blood and Marrow Transplant Clinical Trials Network
Mar 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rainer StorbBrenda M Sandmaier
Dec 11, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Martino IntronaEttore Biagi
Jul 10, 2014·JAMA : the Journal of the American Medical Association·Mohammad Hassan MuradGordon Guyatt
Nov 22, 2014·Blood·Marcos de Lima

❮ Previous
Next ❯

Citations

Mar 24, 2016·Expert Opinion on Emerging Drugs·Natasha Kekre, Joseph H Antin
May 1, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mina RizkDavid S Allan
Jul 12, 2016·Expert Review of Clinical Immunology·F LocatelliA Bertaina
Dec 22, 2016·Immunotherapy·John Girdlestone
Mar 14, 2018·Stem Cells Translational Medicine·Olle RingdenBehnam Sadeghi
Jul 8, 2018·The Journal of Immunology : Official Journal of the American Association of Immunologists·Vera van HoevenMette D Hazenberg
Aug 8, 2018·European Journal of Haematology·Frederick W ThielenCarin A Uyl-de Groot
Oct 10, 2018·Current Opinion in Nephrology and Hypertension·Federica Casiraghi, Giuseppe Remuzzi
Feb 2, 2018·Stem Cell Research & Therapy·Tiankai XuLihua Dong
Apr 16, 2020·Expert Opinion on Investigational Drugs·Sameem M Abedin, Mehdi Hamadani
Apr 26, 2020·Stem Cells·Stuart P Atkinson
Dec 13, 2016·Bone Marrow Transplantation·U SalmenniemiM Korhonen
Jul 1, 2017·Frontiers in Nutrition·Elena ZocchiJosep Bassaganya-Riera
Jan 11, 2018·Therapeutic Advances in Hematology·LaQuisa HillElizabeth Shpall
Jan 1, 2016·Expert Opinion on Orphan Drugs·Anne S RenteriaJames L M Ferrara
Nov 24, 2016·Alimentary Pharmacology & Therapeutics·C GrégoireY Beguin
Feb 14, 2017·Stem Cells Translational Medicine·Christopher R Nitkin, Tracey L Bonfield
Sep 10, 2020·Frontiers in Immunology·Lauren A CallenderCatherine J Betts
May 20, 2020·Journal of Translational Medicine·Christopher J RogersBoris R Minev
Aug 1, 2018·Frontiers of Medicine·Shihua WangRobert Chunhua Zhao
Dec 10, 2019·Npj Regenerative Medicine·Mark F PittengerArnold I Caplan
Jul 29, 2020·Frontiers in Immunology·Felipe Saldanha-AraujoJuliana Lott Carvalho
Aug 9, 2020·International Journal of Environmental Research and Public Health·Hossein HozhabriMeysam Sarshar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.